Study of ASTX029 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the
safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029
administered orally to subjects with advanced solid malignancies who are not candidates for
approved or available therapies.